drugset

drugset / Trial / NCT04796402

A Study to Assess if a Medicine Called Bamlanivimab is Safe and Effective in Reducing Hospitalization Due to COVID-19

NCT04796402 ↗

Phase 4 Unknown 576 enrolled Fraser Health BC Support Unit · collab Centre for Health Evaluation and Outcome Sciences · collab Clinical Trials BC (part of the BC Academic Health Science Network) · collab Fraser Health Authrority Department of Evaluation and Research Services · collab Ministry of Health, British Columbia · collab Surrey Hospital Foundation · collab Surrey Memorial Hospital Clinical Research Unit · collab University of British Columbia · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this research is to test whether a new medication called bamlanivimab is safe and effective at reducing the need for hospitalization due to COVID-19.

Timeline

Start: 2021-03-17
Primary completion: 2021-06-07
Completion: 2021-12-31

Publications

Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bamlanivimab	Monoclonal antibody	700 mg	Intravenous

Indications